Schwenkglenks M - Search Results

1

Physical Activity Interventions for Primary Prevention in Adults: A Systematic Review of Randomized Controlled Trial-Based Economic Evaluations.

Mattli R, Farcher R, Syleouni ME, Wieser S, Probst-Hensch N, Schmidt-Trucksäss A, Schwenkglenks M. Mattli R, et al. Among authors: schwenkglenks m. Sports Med. 2020 Apr;50(4):731-750. doi: 10.1007/s40279-019-01233-3. Sports Med. 2020. PMID: 31755043 Free article. Review.

2

Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.

Szucs TD, Blank PR, Schwenkglenks M, Aapro M. Szucs TD, et al. Among authors: schwenkglenks m. Oncology. 2011;81(1):45-9. doi: 10.1159/000330738. Epub 2011 Sep 15. Oncology. 2011. PMID: 21921645 Free article.

3

Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data.

Speich B, von Niederhäusern B, Schur N, Hemkens LG, Fürst T, Bhatnagar N, Alturki R, Agarwal A, Kasenda B, Pauli-Magnus C, Schwenkglenks M, Briel M; MAking Randomized Trials Affordable (MARTA) Group. Speich B, et al. Among authors: schwenkglenks m. J Clin Epidemiol. 2018 Apr;96:1-11. doi: 10.1016/j.jclinepi.2017.12.018. Epub 2017 Dec 27. J Clin Epidemiol. 2018. PMID: 29288136 Review.

4

How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts.

Wieser S, Riguzzi M, Pletscher M, Huber CA, Telser H, Schwenkglenks M. Wieser S, et al. Among authors: schwenkglenks m. Eur J Health Econ. 2018 Nov;19(8):1149-1161. doi: 10.1007/s10198-018-0963-5. Epub 2018 Feb 22. Eur J Health Econ. 2018. PMID: 29470673 Free article.

5

Physical inactivity caused economic burden depends on regional cultural differences.

Mattli R, Wieser S, Probst-Hensch N, Schmidt-Trucksäss A, Schwenkglenks M. Mattli R, et al. Among authors: schwenkglenks m. Scand J Med Sci Sports. 2019 Jan;29(1):95-104. doi: 10.1111/sms.13311. Epub 2018 Oct 15. Scand J Med Sci Sports. 2019. PMID: 30260508

6

Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation.

Speich B, Schur N, Gryaznov D, von Niederhäusern B, Hemkens LG, Schandelmaier S, Amstutz A, Kasenda B, Pauli-Magnus C, Ojeda-Ruiz E, Tomonaga Y, McCord K, Nordmann A, von Elm E, Briel M, Schwenkglenks M; a collaboration of the MARTA (MAking Randomized Trials Affordable) and ASPIRE (Adherence to Standard Protocol Items: REcommendations for interventional trials) Study Groups. Speich B, et al. Among authors: schwenkglenks m. PLoS One. 2019 Jan 11;14(1):e0210669. doi: 10.1371/journal.pone.0210669. eCollection 2019. PLoS One. 2019. PMID: 30633776 Free PMC article.

7

Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review.

Gubler-Gut BE, Pöhlmann J, Flatz A, Schwenkglenks M, Rohrmann S. Gubler-Gut BE, et al. Among authors: schwenkglenks m. J Cancer Surviv. 2021 Dec;15(6):961-975. doi: 10.1007/s11764-021-01002-0. Epub 2021 Feb 23. J Cancer Surviv. 2021. PMID: 33624172 Free PMC article. Review.

8

Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.

Galactionova K, Salari P, Mattli R, Rachamin Y, Meier R, Schwenkglenks M. Galactionova K, et al. Among authors: schwenkglenks m. Pharmacoeconomics. 2022 Aug;40(8):791-806. doi: 10.1007/s40273-022-01152-8. Epub 2022 Jun 20. Pharmacoeconomics. 2022. PMID: 35723806 Free PMC article.

9

Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.

Galactionova K, Salari P, Mattli R, Rachamin Y, Meier R, Schwenkglenks M. Galactionova K, et al. Among authors: schwenkglenks m. Pharmacoeconomics. 2022 Aug;40(8):835. doi: 10.1007/s40273-022-01171-5. Pharmacoeconomics. 2022. PMID: 35798916 Free PMC article. No abstract available.

10

The economic efficiency of amlodipine in the treatment of coronary atherosclerosis--an analysis based on the PREVENT study.

Cathomas G, Erne P, Schwenkglenks M, Szucs TD. Cathomas G, et al. Among authors: schwenkglenks m. Cardiovasc Drugs Ther. 2002 Jan;16(1):61-6. doi: 10.1023/a:1015323700206. Cardiovasc Drugs Ther. 2002. PMID: 12085980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page